The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 39.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 92%. Our forward projection puts the odds of a 10% gain over the next month near 47%.
Anbio Biotechnology NNNN
Clears both ethical standardsAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally.
read at $9.49
Anbio Biotechnology holds its Distribution at $9.49.
- PHPhase · the trend structure carries the Distribution label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · screen not yet scored
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 55 days |
| Price | $9.49 |
| Valuation | 63.27 trailing · N/A forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | N/A |
The business, in plain words · what the numbers mean
| Trailing P/E | 63.3x expensive — the price assumes strong growth ahead |
| Revenue growth | 73.9% growing very fast |
| Profit margin | 74.1% highly profitable on every dollar of sales |
| Return on equity | 27.0% an exceptional return on shareholder capital |
| Current ratio | 344.31 comfortably covers its short-term bills |
| Market cap | $417M |
| Employees | 27 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Germany and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in NNNN's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
NNNN trades on Nasdaq (the company is based in Germany). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 92%. Our forward projection puts the odds of a 10% gain over the next month near 47%.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $25.35 | -34.5% | · | $655 | -34.5% |
| 2 months | $27.10 | -38.7% | · | $613 | -38.7% |
| 3 months | $22.54 | -26.3% | · | $737 | -26.3% |
| 6 months | $29.21 | -43.2% | · | $569 | -43.2% |
| 1 year | $8.66 | +91.7% | · | $1,917 | +91.7% |
Historical returns from market close data. Past performance does not guarantee future results.